300+ investors in your industry, stage, and region Get
Any industry
Big Data
Video Games
Clean Energy
Google
Construction
Hospitality
EdTech
Consumer
Artificial Intelligence
Local
Enterprise Software
Platforms
Travel
InsurTech
Oil and Gas
Retail
Social Impact
Cryptocurrency
Film
Payments
Photography
Email
CleanTech
Energy
Marketplace
SaaS
Restaurants
Organic Food
Fitness
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Blockchain
B2B
Social Network
Education
Wellness
Medical Device
Mobile
Sports
Legal
Automotive
eSports
Biotechnology
Software
Renewable Energy
Theatre
Crowdfunding
Recruiting
Web3
Medical
Infrastructure
Beauty
Fashion
Venture Capital
Social
LGBT
Cannabis
Climate
Celebrity
Wine and Spirits
Food and Beverage
Publishing
Life Science
Mobile Apps
Music
Real Estate
Sporting Goods
Art
Digital Media
FinTech
Manufacturing
Finance
Financial Services
Social Media
Franchise
Mobile Advertising
Non Profit
Internet
Android
Biotech
Sustainability
Transportation
Proptech
Impact
Hardware
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
United Kingdom
Hong Kong
Thailand
United Arab Emirates
Greece
Benin
Croatia
Japan
South Korea
Burkina Faso
Africa
Brazil
Gibraltar
Egypt
Kyrgyzstan
Zambia
Zimbabwe
Sweden
Taiwan
Norway
Tajikistan
Tunisia
Liberia
Malawi
Mexico
Nigeria
Russian Federation
Togo
Nepal
Guinea
Haiti
Iran
Isle of Man
Lesotho
Madagascar
Pakistan
Romania
Singapore
Oceania
LATAM
Puerto Rico
Oman
Poland
Guernsey
Cameroon
Andorra
Colombia
Sudan
China
Armenia
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Namibia
Mozambique
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Morocco
Moldova
Botswana
Seychelles
Paraguay
South Africa
Canada
Ireland
France
Georgia
Denmark
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Portugal
Rwanda
Sierra Leone
Senegal
El Salvador
Tanzania
India
Germany
United States
Indonesia
Middle East
Bermuda
Dominican Republic
Asia
Albania
Qatar
Spain
Angola
Europe
Cyprus
Argentina
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Bulgaria
Ecuador
Estonia
Faroe Islands
Jersey
Bahrain
Bahamas
Bolivia
Belize
Algeria
Italy
Finland
Belarus
Hungary
Grenada
Israel
Lithuania
Honduras
Iceland
Cambodia
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Alice Newcombe-Ellis, board of directors at Mogrify

Alice Newcombe-Ellis

board of directors @ Mogrify

Alice Newcombe-Ellis is a Series A investor at Mogrify focused on Software and Biotechnology. Alice Newcombe-Ellis is Founding and Managing Partner at Ahren Innovation Capital.

Total investments:
12
Last investment:
Lead investor:
50%

Last updated:

Industries Alice Newcombe-Ellis invests in

SoftwareBiotechnologyInformation TechnologyArtificial IntelligenceMineral

Stages Alice Newcombe-Ellis invests in

Series ASeries BSeedPre-SeedConvertible Note

Countries Alice Newcombe-Ellis invests in

United StatesUnited KingdomIsrael

Contacts

TypeContactValidation
Work email
Personal email
Work phone
Personal phone
Socials

Sign up to unlock verified contacts

Unlock Contacts

Investment Focus

Industry

  • Software 2 (17%)
  • Biotechnology 2 (17%)
  • Information Technology 2 (17%)
  • Artificial Intelligence 2 (17%)
  • Mineral 1 (8%)
See all 23 industries →

Stage

  • Series A 5 (42%)
  • Series B 3 (25%)
  • Seed 1 (8%)
  • Pre-Seed 1 (8%)
  • Convertible Note 1 (8%)
See all 6 stages →

Country

  • United States 6 (50%)
  • United Kingdom 2 (17%)
  • Israel 1 (8%)

Investments

CompanyDescriptionRoundLinks
Heirloom Heirloom
Heirloom is a provider of direct air capture technology to enhance the natural process of CO2 absorption from the atmosphere. Its technology accelerates limestone's ability to capture carbon dioxide, storing it permanently underground while operating with renewable energy. $150M / Series B / Dec 04, 2024
Rubedo Life Sciences Rubedo Life Sciences
Rubedo Life Sciences mission is to treat age-related diseases to extend health-span targeting senescence and stem cells. $40M / Series A / Apr 22, 2024
Ambi Robotics Ambi Robotics
Ambi Robotics is an artificial intelligence (AI) and robotics company developing advanced solutions that scale e-commerce operations to meet demand while empowering humans to work smarter. The company was founded in 2018 and is based in Berkeley, California, United States. $32M / Series A / Oct 14, 2022
Ambi Robotics Ambi Robotics
Ambi Robotics is an artificial intelligence (AI) and robotics company developing advanced solutions that scale e-commerce operations to meet demand while empowering humans to work smarter. The company was founded in 2018 and is based in Berkeley, California, United States. $32M / Convertible Note / Oct 14, 2022
AI21 Labs AI21 Labs
AI21 Labs is a creator of generative artificial intelligence and massive language models, as well as tools for creating artificial intelligence systems with extraordinary understanding and generation of natural language. The company's tool captures real intelligence and rewrites writing to say exactly what is meant; it transforms the waypeople read and write, empowering them in the process; it is an artificial intelligence-based writing companion that understands context and meaning; and it helps people read more efficiently by providing summaries, allowing customers to understand, analyze, and visualize abstract knowledge structures. $64M / Series B / Jul 12, 2022
Heirloom Heirloom
Heirloom is a provider of direct air capture technology to enhance the natural process of CO2 absorption from the atmosphere. Its technology accelerates limestone's ability to capture carbon dioxide, storing it permanently underground while operating with renewable energy. $53M / Series A / Mar 17, 2022
New Culture New Culture
New Culture is a food and beverage company that focuses on revolutionizing how cheese is made. It was founded in 2018 and headquartered in San Francisco, California. $25M / Series A / Nov 22, 2021
Adrestia Therapeutics Adrestia Therapeutics
Adrestia is developing therapeutics that work in an entirely new way – restoring the biological balance in damaged, diseased or dying cells $232.6M / Series A / Dec 18, 2020
Zapata Quantum Zapata Quantum
Zapata Computing is a quantum software company that offers computing solutions for industrial and commercial use. It provides hardware-agnostic solutions for simulation, optimization, and machine learning applications in chemistry, finance, logistics, pharmaceuticals, engineering, and materials.Zapata Computing is a spun out of Harvard Universitylaunched by a group of Harvard scientists, including Alán Aspuru-Guzik.The company was founded in 2017 and is headquartered in Boston, Massachusetts. $38M / Series B / Nov 19, 2020
Nu Quantum Nu Quantum
Nu Quantum is a telecommunications company that develops end-to-end quantum cryptography systems.It secures communications within and between cities through urban and satellite free-space optical links. The system helps with the realization of commercial deliverable photonic technologies by combining novel materials and semiconductor technology.This enables clients to secure the exchange of cryptographic keys for the ultra-sensitive detection of light.Yuri Andersson, Mete Atatüre, and Carmen Berraquero founded Nu Quantum in Cambridge, Cambridgeshire in 2018. $2.7M / Seed / Oct 05, 2020
See all 12 investments →

Co-Investors

Mogrify

About Mogrify

VC Fund · Cambridge, United Kingdom

Mogrify® has developed a proprietary suite of platform technologies that utilize a systematic big-data approach to direct cellular reprogramming (Rackham et al., Nature Genetics, 2016) and the maintenance of cell identity (Kamaraj et al., Cell Systems 2020). The platforms, MOGRIFY® and epiMOGRIFY®, developed over a 12-year period via amulti-national research collaboration, deploy next-generation sequencing, gene regulatory and epigenetic network data to enable the prediction of the transcription factors and growth factors required to produce any target human cell type from any source human cell type.The platforms can be used to enhance existing stem-cell forward programming methods, or bypass development pathways altogether, affecting a direct transdifferentiation between a mature cell type to another mature cell type.Mogrify is applying its proprietary and award-winning platforms to generate the functional cell types required to transform the lives of patients, by delivering a novel class of in vivo reprogramming therapies across ophthalmology, otology, metabolic and other areas of degenerative disease.Uniquely positioned to address a regenerative medicine market estimated to be worth $150 billion USD by 2028, Mogrify is commercializing its technology via a combination of in vivo reprogramming therapy development, co-development partnerships, as well as the exploitation of the platform in other therapeutic and non-therapeutic applications.

Mogrify Contacts

NameEmailPhoneSocials
Alastair Kilgour
Alastair Kilgour Investment Director
Alice Newcombe-Ellis
Alice Newcombe-Ellis board of directors
Joe Foster
Joe Foster Chief Operating Officer
Jonathan Appleby
Jonathan Appleby Chief Scientific Officer
Jose Polo
Jose Polo Co-Founder

Sign up to unlock verified contacts

Unlock Contacts

See all contacts →

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Big Data
Video Games
Clean Energy
Google
Construction
Hospitality
EdTech
Consumer
Artificial Intelligence
Local
Enterprise Software
Platforms
Travel
InsurTech
Oil and Gas
Retail
Social Impact
Cryptocurrency
Film
Payments
Photography
Email
CleanTech
Energy
Marketplace
SaaS
Restaurants
Organic Food
Fitness
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Blockchain
B2B
Social Network
Education
Wellness
Medical Device
Mobile
Sports
Legal
Automotive
eSports
Biotechnology
Software
Renewable Energy
Theatre
Crowdfunding
Recruiting
Web3
Medical
Infrastructure
Beauty
Fashion
Venture Capital
Social
LGBT
Cannabis
Climate
Celebrity
Wine and Spirits
Food and Beverage
Publishing
Life Science
Mobile Apps
Music
Real Estate
Sporting Goods
Art
Digital Media
FinTech
Manufacturing
Finance
Financial Services
Social Media
Franchise
Mobile Advertising
Non Profit
Internet
Android
Biotech
Sustainability
Transportation
Proptech
Impact
Hardware
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
United Kingdom
Hong Kong
Thailand
United Arab Emirates
Greece
Benin
Croatia
Japan
South Korea
Burkina Faso
Africa
Brazil
Gibraltar
Egypt
Kyrgyzstan
Zambia
Zimbabwe
Sweden
Taiwan
Norway
Tajikistan
Tunisia
Liberia
Malawi
Mexico
Nigeria
Russian Federation
Togo
Nepal
Guinea
Haiti
Iran
Isle of Man
Lesotho
Madagascar
Pakistan
Romania
Singapore
Oceania
LATAM
Puerto Rico
Oman
Poland
Guernsey
Cameroon
Andorra
Colombia
Sudan
China
Armenia
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Namibia
Mozambique
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Morocco
Moldova
Botswana
Seychelles
Paraguay
South Africa
Canada
Ireland
France
Georgia
Denmark
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Portugal
Rwanda
Sierra Leone
Senegal
El Salvador
Tanzania
India
Germany
United States
Indonesia
Middle East
Bermuda
Dominican Republic
Asia
Albania
Qatar
Spain
Angola
Europe
Cyprus
Argentina
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Bulgaria
Ecuador
Estonia
Faroe Islands
Jersey
Bahrain
Bahamas
Bolivia
Belize
Algeria
Italy
Finland
Belarus
Hungary
Grenada
Israel
Lithuania
Honduras
Iceland
Cambodia
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Alice Newcombe-Ellis invest in?

Alice Newcombe-Ellis invests primarily in Software, Biotechnology and Information Technology startups, most often at Series A and Series B stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

How do I contact Alice Newcombe-Ellis?

Public channels for Alice Newcombe-Ellis include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

When did Alice Newcombe-Ellis last invest?

The most recent investment recorded for Alice Newcombe-Ellis closed in Dec 2024. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Alice Newcombe-Ellis Alice Newcombe-Ellis Find email